Immunovant, Inc.

IMVT

$39.12

-0.94%

2026-09-03 16:00:01 EDT-$0.37

Healthcare

Biotechnology

NASDAQ

Active Trading

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of ...

Price Action of IMVT

$39.12

-0.94%-$0.37

High—

Low—

52W High-13.9%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Immunovant, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to advancing innovative therapies for autoimmune diseases. The company's primary focus is batoclimab, a fully human monoclonal antibody engineered to block the neonatal Fc receptor (FcRn), a mechanism that plays a role in certain autoimmune conditions. Batoclimab is ...Immunovant, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to advancing innovative therapies for autoimmune diseases. The company's primary focus is batoclimab, a fully human monoclonal antibody engineered to block the neonatal Fc receptor (FcRn), a mechanism that plays a role in certain autoimmune conditions. Batoclimab is currently undergoing Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with additional Phase II studies for warm autoimmune hemolytic anemia. The company was founded in 2018 and is headquartered in Durham, North Carolina, though originally operating from New York, and is a subsidiary of Roivant Sciences Ltd. As of the latest data, Immunovant has 315 full-time employees and is led by CEO Eric Venker, MD, PharmD, who has been with the company since 2020. Financially, Immunovant is a clinical-stage company with no approved products, and its market capitalization is approximately $8.25 billion, reflecting investor confidence in its pipeline. The company has a strong cash position with a current ratio of 7.27 and no debt, but it is incurring significant operating losses due to heavy investment in research and development, with R&D expenses constituting over 70% of revenue (which is minimal). The company's enterprise value is about $7.45 billion, indicating a high valuation relative to its early stage. Key financial metrics show negative profitability ratios, as expected for a biotech in development, with a net margin of -75.9%. Immunovant's strategic focus is to bring batoclimab to market to address unmet needs in autoimmune diseases, and it continues to expand its pipeline, including IMVT-1402, a next-generation FcRn inhibitor. The company's mission is to enable normal lives for patients with autoimmune conditions, and it emphasizes patient-centric approaches. With a strong balance sheet and a clear clinical pathway, Immunovant is positioned to potentially become a major player in immunology, though it faces typical risks of clinical trial failures and regulatory hurdles.ExpandCollapse

Founded

2018

Employees

315

CEO

Eric Venker

Full Name

Immunovant, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-69.59%

Market Cap

$8.07B

Current Ratio

7.27

WACC

8.34%

ROIC

-73.28%

Contact Information

https://immunovant.com

917 580 3099

1000 Park Forty Plaza, Durham, NY 27713

Key Metrics of IMVT

Snapshot

Latest / TTM · 6 periods

Market Cap

$8.07B

ROCE

-76.0%

EV / EBITDA

-13.52x

-13.5% YoY

FCF Yield

-5.1%

+3.9% YoY

Cash Conversion Cycle

-17927.1d

Current Ratio

7.27

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of IMVT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

97.1%

Net Margin

-7585.9%

P/E Ratio

-13.88x

n/a

Debt / Equity

0.00

n/a

Current Ratio

7.27

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of IMVT

Upcoming

Dec 30, 2026
Q3 FY2027 · Estimated results
Est. EPS $-0.73 · Revenue $7.09M · 4 analysts
Mar 30, 2027
Q4 FY2027 · Estimated results
Est. EPS $-0.73 · Revenue $14.40M · 1 analysts
Mar 31, 2027
FY2027 · Estimated annual results
Est. EPS $-2.94 · Revenue $6.64M · 9 analysts
Jun 30, 2027
Q1 FY2028 · Estimated results
Est. EPS $-0.73 · Revenue $7.09M · 1 analysts

Recent history

Aug 6, 2026
Q1 FY2027 · Results reported
EPS $-0.75 · Revenue $7.09M
View filing
May 20, 2026
FY2026 · Annual results
EPS $-2.77 · Revenue $0.00
View filing
Feb 6, 2026
Q3 FY2026 · Results reported
EPS $-0.61 · Revenue $0.00
View filing
Nov 10, 2025
Q2 FY2026 · Results reported
EPS $-0.73 · Revenue $0.00
View filing
Aug 11, 2025
Q1 FY2026 · Results reported
EPS $-0.71 · Revenue $0.00
View filing
May 29, 2025
FY2025 · Annual results
EPS $-2.73 · Revenue $0.00
View filing

Financial Statements of IMVT

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-505.6M	-22.2%	-3.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-407.3M	-8.1%	-30.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	-39.0%	-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	9.09x	-18.6%	-20.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$957.6M	+23.4%	-10.9%

Actual vs Estimate

A Mar 31Q Dec 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-2.77 vs -2.61	-6.1%	-0.75 vs -0.73	-2.8%
Revenue Surprise	$0 vs $10.5M	-100.0%	$7.1M vs $7.1M	0.0%

Insider Transactions of IMVT

Acquisitions (A)

Since Jul 8, 2026

Disposals (D)

Since Jul 8, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 28, 2026	Pande Atul	director	Common Stock	A	1,500	$8.43
Aug 28, 2026	Pande Atul	director	Common Stock	D	1,500	$43.27
Aug 28, 2026	Pande Atul	director	Stock Option (right to buy)	D	1,500	$8.43
Aug 20, 2026	Gloria Melanie	officer: Chief Operating Officer	Common Stock	D	3,056	$44.16
Jul 24, 2026	Pande Atul	director	Common Stock	A	1,500	$8.43

Earnings Call Transcript of IMVT

1 transcript segments

Q1 2027

Unknown Speaker

Operator: Good day, and thank you for standing by. Welcome to Roivant's First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's call is being recorded. I would now like to hand the conference over to your first speaker today, Stephanie Lee. Thank you. Please go ahead. Stephanie Lee Griffin: Good morning, and thanks for joining today's call to review Roivant's financial results for the first quarter ended June 30, 2026. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we have filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I'll turn it over to Matt. Matthew Gline: Thank you, Steph, and good morning, everybody, and thank you for joining. This is a little bit of a time before the storm moment for us. And so a pretty quiet quarter and maybe not the most interesting of our earnings calls in recent memory. But nonetheless, a lot of great progress in the business. And certainly, we're expecting a Genpact second half, as I'll get to in a moment. So I'll be relatively brief in my remarks, and then we'll go to Q&A. I want to start on Slide 4. This is a slide we took from our own prior deck. This is from the Investor Day that we did in December of last year, and this was a list of our priorities for the year. And we're sitting here a little bit more than halfway through the year. So just wanted to highlight that it's gone well for us, but we feel really good about the setup. And so on Slide 5, looking across the list here, we've got brexpiprazole expected to launch by the end of September. Obviously, we got priority review and our PDUFA date, as you said, is this quarter. We had great data from 1402 and DCRA study that we presented on our last quarterly call. Probably the most notable update for today in the top center of this slide is that we've now enrolled patients in the Phase III study in cutaneous sarcoidosis for brexpiprazole, which follows on the positive results that we had in our Phase II data, which I think we announced on our first quarterly call of this year, earlier in the calendar year. We've now received the initial payment from Moderna in the settlement and that -- the sort of second part of that, the 1498 part of that case is progressing, and we filed international proceedings against Pfizer and BioNTech in that case. And finally, earlier this year, we added LPP as a fourth brexpiprazole indication. And as I'll remind people later today, …

Leadership Team of IMVT

14 executives

Name	Title	Compensation	Gender	Year Born	Status
Eric Venker	Chief Executive Officer & Director	USD 1,148,128	—	1987	Active
Melanie Gloria	Chief Operating Officer	USD 759,066	Female	1978	Active
Jay S. Stout	Chief Technology Officer	USD 757,675	—	1963	Active
Christopher Van Tuyl	Chief Legal Officer & Corporate Secretary	USD 757,089	Male	1975	Active
Tiago Girao	Chief Financial Officer	USD 691,212	Male	1979	Active
Frank Torti	Executive Chairperson of the Board	USD 92,500	—	1979	Active
Luciano Pollastrini	Senior Vice President of CMC Technical Operations	—	Male	—	Active
Becky Merlina	Senior VP & Global Head of Quality	—	Female	—	Active
Khira Gabliani	Chief of Staff to the CEO	—	Female	—	Active
Lorna Liganor	Senior Vice President of Clinical Operations	—	Female	—	Active
Ruby Grewal	Senior Vice President of Commercial	—	Female	—	Active
Sheetal Patel	Senior Vice President of Clinical Development	—	Female	—	Active
Yan Zheng	Senior Vice President of Biostatistics, Programming & Data Management	—	Female	—	Active
Christine Blodgett	Senior Vice President of Human Resources	—	Female	—	Active

Recent News of IMVT

Seeking Alpha8/6/2026Neutral

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

MarketBeat8/6/2026Neutral

Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.

Zacks Investment Research8/6/2026Neutral

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

GlobeNewsWire8/6/2026Neutral

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.

Seeking Alpha7/27/2026Neutral

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.

Historical Employee Count of IMVT

Current

315

Change

-12.98%

Minimum

124

Maximum

362

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Mar 31, 2026	315	10-K	May 20, 2026	View
Mar 31, 2025	362	10-K	May 29, 2025	View
Mar 31, 2024	207	10-K	May 29, 2024	View
Mar 31, 2023	164	10-K	May 22, 2023	View
Mar 31, 2022	124	10-K	Jun 8, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Immunovant, Inc.